HUB2 Antibody

What is HABP2 and what are its key biological functions?

HABP2 (Hyaluronan-binding protein 2), also known as Factor VII-activating protease (FSAP), plasma hyaluronan-binding protein (PHBP), or hepatocyte growth factor activator-like protein (HGFAL), is a serine protease with multiple biological functions. It cleaves the alpha-chain at multiple sites and the beta-chain between 'Lys-53' and 'Lys-54' of fibrinogen but does not initiate fibrin clot formation directly. HABP2 converts inactive single chain urinary plasminogen activator (pro-urokinase) to its active two-chain form and activates coagulation factor VII. Recent research suggests it may function as a tumor suppressor by negatively regulating cell proliferation and migration .

What are the common applications of HABP2 antibodies in research?

HABP2 antibodies are commonly employed in several laboratory techniques:

• Western blot (WB): For detecting HABP2 protein in cell/tissue lysates

• Immunocytochemistry/Immunofluorescence (ICC/IF): For visualizing cellular localization

• Flow cytometry (intracellular): For quantifying HABP2 expression in cell populations

• Immunohistochemistry (IHC): For detecting HABP2 in tissue specimens

These applications allow researchers to investigate HABP2 expression patterns, protein interactions, and potential roles in physiological and pathological processes .

Which species reactivity should I consider when selecting a HABP2 antibody?

When selecting a HABP2 antibody, consider the species origin of your samples. Available antibodies often have verified reactivity with human, mouse, and rat samples. Species cross-reactivity is an essential consideration in antibody selection and should be explicitly verified for your specific application. Some antibodies may work with species not explicitly tested based on protein homology, but this should be experimentally validated before proceeding with critical experiments .

How can I design proper controls for HABP2 antibody validation in my experimental system?

Proper controls for HABP2 antibody validation should include:

• Positive controls: Use tissues or cell lines known to express HABP2 (e.g., MCF7, A549, HepG2 cells for human samples; brain or heart tissue for mouse/rat samples)

• Negative controls:

  • Isotype controls using non-specific antibodies of the same isotype

  • Tissues or cell lines with confirmed absence of HABP2 expression

  • HABP2 knockout or knockdown samples when available

• Specificity controls:

  • Peptide competition assays

  • Comparison with alternative antibodies targeting different epitopes of HABP2

• Technical controls:

  • Secondary antibody-only controls to assess background

  • Concentration gradients to determine optimal antibody dilution

These controls help ensure that the observed signal is specific to HABP2 and not due to non-specific binding or background issues .

What are the critical considerations for epitope mapping of HABP2 antibodies?

Epitope mapping for HABP2 antibodies requires understanding which specific region of the protein the antibody recognizes. This knowledge is crucial for interpreting results, especially when studying protein interactions or domains with specific functions. The process typically involves:

• Generation of deletion mutants of full-length HABP2

• Expression of these mutants followed by immunoblot analysis

• Synthesis of overlapping peptides covering regions of interest

• Analysis of antibody binding to these peptides using assays like AlphaScreen

Understanding the epitope can help predict potential cross-reactivity with similar proteins and determine if the antibody might interfere with protein-protein interactions or enzymatic activity. This approach is similar to what was used for HBc antibody epitope mapping, where researchers identified the Arginine-Rich Domain (ARD) as the binding region for their monoclonal antibody .

What characterization data should accompany a HABP2 antibody for reliable research applications?

A properly characterized HABP2 antibody should be accompanied by the following data:

This comprehensive characterization ensures reproducibility across laboratories and experiments, addressing the widespread issue of antibody reliability in research .

How should I approach antibody validation when working with HABP2 in non-standard experimental models?

When using HABP2 antibodies in non-standard models (uncommon cell lines, tissues, or species), adopt a systematic validation approach:

• Sequential validation:

  • Begin with bioinformatic analysis to assess HABP2 sequence homology between your model and validated species

  • Perform Western blot to confirm antibody binding at the expected molecular weight (observed band ~75 kDa for HABP2)

  • Follow with immunofluorescence/immunohistochemistry to assess localization patterns

• Alternative methods confirmation:

  • Validate findings using orthogonal methods (e.g., mass spectrometry)

  • Consider mRNA expression analysis (RT-PCR or RNAseq) to correlate with antibody staining patterns

• Context-specific controls:

  • Generate or obtain model-specific negative controls (CRISPR knockout, siRNA)

  • Perform peptide competition assays with recombinant HABP2 from your model organism

This rigorous approach helps establish confidence in antibody specificity for your particular experimental system .

What strategies can I employ when HABP2 antibody performance varies between applications?

When experiencing variable performance across applications:

• Application-specific optimization:

  • For Western blot: Test different blocking agents, transfer methods, and antigen retrieval approaches

  • For ICC/IF: Optimize fixation methods (paraformaldehyde vs. methanol) and permeabilization conditions

  • For Flow cytometry: Adjust permeabilization protocols and antibody concentrations

• Epitope accessibility considerations:

  • Native vs. denatured conditions may affect epitope exposure

  • Different fixation methods can alter protein conformation

  • Consider whether post-translational modifications might block the epitope

• Cross-validation approach:

  • Test multiple antibodies recognizing different HABP2 epitopes

  • Compare monoclonal and polyclonal antibodies when available

  • Validate findings with complementary non-antibody methods

For example, the ab181837 antibody has been successfully used in Western blot (1/10000 dilution), flow cytometry (1/20 dilution), and other applications, but each required specific optimization .

How can I address non-specific binding issues with HABP2 antibodies?

Non-specific binding can be addressed through these methodological adjustments:

• Blocking optimization:

  • Test alternative blocking agents (BSA, normal serum, commercial blockers)

  • Increase blocking time and/or concentration

  • Include detergents like Tween-20 in wash buffers

• Antibody dilution optimization:

  • Perform titration experiments to determine optimal concentration

  • Consider using higher dilutions (1/10000 for Western blot has been effective for some HABP2 antibodies)

• Pre-adsorption techniques:

  • Pre-incubate antibody with tissues/cells known to produce non-specific binding

  • Use commercially available antibody pre-adsorption kits

• Signal enhancement with minimal background:

  • Test alternative detection systems (HRP vs. fluorescence)

  • Use signal amplification methods with enhanced specificity

  • Consider more stringent washing protocols

These approaches can significantly improve signal-to-noise ratio and ensure that observed signals truly represent HABP2 protein .

How should HABP2 antibody data be interpreted in the context of tumor biology research?

When using HABP2 antibodies in cancer research, consider these interpretation frameworks:

• Expression pattern analysis:

  • Compare HABP2 levels between tumor and matched normal tissues

  • Assess subcellular localization changes in malignant cells

  • Correlate expression with clinical parameters and outcomes

• Functional context interpretation:

  • Consider HABP2's potential tumor suppressor role when analyzing expression changes

  • Interpret findings in light of HABP2's effects on cell proliferation and migration

  • Assess correlation with other coagulation factors or proteases in the tumor microenvironment

• Data integration approach:

  • Combine antibody-based detection with genomic/transcriptomic data

  • Correlate protein expression with mutation or methylation status of HABP2

  • Consider pathway analysis incorporating HABP2 interactors

For example, reduced HABP2 expression might suggest loss of tumor suppressor function, while altered subcellular localization could indicate dysregulation of specific signaling pathways .

What considerations should be made when using HABP2 antibodies in multiplex imaging studies?

For multiplex imaging involving HABP2 antibodies:

• Panel design considerations:

  • Select antibodies with minimal spectral overlap

  • Ensure compatibility of fixation and antigen retrieval methods across all antibodies

  • Consider antibody species origin to avoid cross-reactivity between secondary antibodies

• Validation requirements:

  • Validate each antibody individually before multiplex experiments

  • Perform controls with single antibody staining to establish baseline signals

  • Include appropriate isotype controls for each primary antibody

• Data analysis approach:

  • Employ computational methods to address spectral overlap

  • Use cell segmentation algorithms for precise localization

  • Quantify co-localization with appropriate statistical methods

• Documentation and reporting:

  • Create detailed Antibody Validation Reports (AVRs) for each antibody in the panel

  • Include information on UniProt accession numbers, RRIDs, and experimental conditions

  • Document positive and negative control data for reproducibility

Multiplex approaches require particularly rigorous validation to ensure that signals are specific and that antibodies do not interfere with each other's binding .

What are the current limitations in HABP2 antibody research that need to be addressed?

Current limitations in HABP2 antibody research include:

• Validation inconsistencies: The antibody characterization crisis affects HABP2 research, with potential variability in antibody quality and characterization standards. Approximately 50% of commercial antibodies fail to meet basic characterization standards, leading to questionable research findings .

• Species cross-reactivity challenges: While some HABP2 antibodies work across human, mouse, and rat samples, comprehensive validation across evolutionary diverse models is lacking.

• Context-dependent performance: Environmental factors, fixation conditions, and experimental variables can affect antibody performance in unpredictable ways.

• Limited recombinant options: Transition to recombinant antibody technology for HABP2 detection would enhance reproducibility but remains incomplete.

Future directions should focus on generating comprehensive validation data, developing recombinant antibody alternatives, and establishing community standards for HABP2 antibody validation across diverse experimental systems.

How can researchers contribute to improving antibody validation standards in the HABP2 field?

Researchers can advance antibody validation standards by:

• Implementing rigorous validation protocols:

  • Apply multiple validation methods for each antibody

  • Include appropriate positive and negative controls

  • Document validation data comprehensively

• Sharing validation data:

  • Submit detailed Antibody Validation Reports (AVRs) to repositories

  • Include validation methods and results in publications

  • Specify exact antibody details (catalog numbers, lot numbers, RRIDs)

• Adopting community standards:

  • Follow guidelines from organizations focused on antibody quality

  • Participate in collaborative validation initiatives

  • Advocate for standardized reporting requirements in journals

• Supporting recombinant antibody development:

  • Transition from hybridoma-produced to recombinant antibodies

  • Share antibody sequences when possible

  • Validate antibodies across multiple applications